Pliant Therapeutics Inc. (PLRX)
3.03
0.03 (1.00%)
At close: Feb 20, 2025, 3:59 PM
3.07
1.38%
After-hours: Feb 20, 2025, 06:25 PM EST
undefined% (undefined)
| Bid | 3 |
| Market Cap | 184.23M |
| Revenue (ttm) | - |
| Net Income (ttm) | - |
| EPS (ttm) | -3.35 |
| PE Ratio (ttm) | -0.9 |
| Forward PE | n/a |
| Analyst | Hold |
| Ask | 3.14 |
| Volume | 1,582,820 |
| Avg. Volume (20D) | 1,442,671 |
| Open | 2.97 |
| Previous Close | 3.00 |
| Day's Range | 2.92 - 3.15 |
| 52-Week Range | 2.43 - 18.00 |
| Beta | undefined |
About PLRX
Pliant Therapeutics, Inc., a clinical stage biopharmaceutical company, discovers, develops, and commercializes novel therapies for the treatment of fibrosis and related diseases in the United States. Its lead product candidate is PLN-74809, an oral small-molecule dual selective inhibitor of avß6 and avß1 integrins, which is in three Phase 2a trials. The company also develops PLN-1474, a small-molecule selective inhibitor of avß1, which completed ...
Industry Biotechnology
Sector Healthcare
IPO Date Jun 3, 2020
Employees 166
Stock Exchange NASDAQ
Ticker Symbol PLRX
Website https://pliantrx.com
Analyst Forecast
According to 10 analyst ratings, the average rating for PLRX stock is "Hold." The 12-month stock price forecast is $4, which is an increase of 32.12% from the latest price.
Buy 40.00%
Hold 60.00%
Sell 0.00%
Next Earnings Release
Pliant Therapeutics Inc. is scheduled to release its earnings on Mar 3, 2025,
during market hours.
Analysts project revenue of ... Unlock content with Pro Subscription
Analysts project revenue of ... Unlock content with Pro Subscription
1 week ago
+20.96%
Pliant Therapeutics shares are trading higher afte...
Unlock content with
Pro Subscription
1 week ago
-60.59%
Pliant Therapeutics shares are trading lower after the company paused enrollment in its BEACON-IPF Phase 2b trial of bexotegrast in patients with idiopathic pulmonary fibrosis.
